ROIV — Roivant Sciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapNeutral

Annual income statement for Roivant Sciences, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	67.7	23.8	55.3	61.3	125
Cost of Revenue
Gross Profit	66.6	21.7	46.3	48.2	109
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	493	979	1,335	1,207	-4,150
Operating Profit	-425	-956	-1,280	-1,146	4,275
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-561	-899	-924	-1,225	4,253
Provision for Income Taxes
Net Income After Taxes	-568	-900	-924	-1,230	4,231
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	1,201	-809	-845	-1,009	4,349
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,123	-809	-845	-1,009	4,349
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.974	-1.29	-0.783	-1.6	1.02
Dividends per Share